

Behrouz Vaziri

Vaziri.b@noargen.com

Education

1997 - 1998 Centro de Ingenieria Genetica y Biotenologia Havana, Cuba
PostDoc, Protein Characterization
1990 - 1994 Faculty of Medicine, Tehran Medical University Tehran, Iran
Ph.D., Immunology
1984 - 1990 Faculty of Pharmacy, Tehran Medical University Tehran, Iran
Pharm. D.

Work experience

1998-Date *Medical Biotechnology Department*, Pasteur Institute of Iran, Tehran, Iran
Associate Professor
Set up the protein chemistry and proteomics Unit.

2015-Date *National Certified Laboratory* (Biopharmaceutical Quality Control)
Head of the Laboratory

2015-2018 *Noargen Co.* Tehran Iran
CEO

Development of Pulmonary surfactant, recombinant EGF, and recombinant HPV vaccine.

2015-Date *National Board of System Biology*, Ministry of Health and Medical Education
Member

2008-2014 *AryoGen BioPharma*, Alborz, Iran
CEO

Development and introducing rFVIIa, Rituximab, and Ethenrecept to the Iran market.

2004-2008 *Medical Biotechnology Department*, Pasteur Institute of Iran, Tehran, Iran
Head of the Biotechnology Department

2000-2008 *CinnaGen Co.*, Tehran, Iran
Scientific Consultant

In design and performance of biopharmaceutical and synthetic peptides' production and quality control.

Publications

1. Fouladiha H, Marashi SA, Torkashvand F, Mahboudi F, Lewis NE, Vaziri B. A metabolic network-based approach for developing feeding strategies for CHO cells to increase monoclonal antibody production. *Bioprocess Biosyst Eng.* 2020. DOI: 10.1007/s00449-020-02332-6
2. Beiranvand, E., Torkashvand, F., Ostad, S.N., Mirzaie, M., Ardakani, E.M., Zandi, F., Sardari, S., Salekdeh, G.H., Shokrgozar, M.A., Vaziri, B. Proteomics analysis of trastuzumab toxicity in H9c2 cardiomyoblast cell line and its inhibition by carvedilol. *Curr Pharm Biotechnol.* 2020. DOI: 10.2174/1389201021666200515135548
3. Beiranvand E, Ostad SN, Ardakani EM, Torkashvand F, Sardari S, Vaziri B. In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. *Drug Res (Stuttg).* 2020;70(4):165-9.

4. Fazel R, Guan Y, Vaziri B, Krisp C, Heikaus L, Saadati A, et al. Structural and In Vitro Functional Comparability Analysis of Altebrel, a Proposed Etanercept Biosimilar: Focus on Primary Sequence and Glycosylation. *Pharmaceuticals (Basel)*. 2019;12(1).
5. Torkashvand F, Mahboudi F, Vossoughi M, Fatemi E, Moosavi Basri SM, Heydari A, et al. Quantitative Proteomic Analysis of Cellular Responses to a Designed Amino Acid Feed in a Monoclonal Antibody Producing Chinese Hamster Ovary Cell Line. *Iran Biomed J*. 2018;22(6):385-93.
6. Khodabakhsh F, Norouzian D, Vaziri B, Ahangari Cohan R, Sardari S, Mahboudi F, et al. Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties. *Artif Cells Nanomed Biotechnol*. 2018;46(7):1402-14.
7. Torkashvand F, Vaziri B. Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components. *Iran Biomed J*. 2017;21(3):131-41.
8. Sadeghi N, Iacobelli M, Vaziri B, Kahn D, Hoppensteadt D, Guler N, et al. Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates. *Clin Appl Thromb Hemost*. 2017;23(3):211-20.
9. Raigani M, Rouini MR, Golabchifar AA, Mirabzadeh E, Vaziri B, Barkhordari F, et al. Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats. *Sci Rep*. 2017;7:43028.
10. Nematpour F, Mahboudi F, Vaziri B, Khalaj V, Ahmadi S, Ahmadi M, et al. Evaluating the expression profile and stability of different UCOE containing vector combinations in mAb-producing CHO cells. *BMC Biotechnol*. 2017;17(1):18.
11. Karami-Zarandi M, Douraghi M, Vaziri B, Adibhesami H, Rahbar M, Yaseri M. Variable spontaneous mutation rate in clinical strains of multidrug-resistant *Acinetobacter baumannii* and differentially expressed proteins in a hypermutator strain. *Mutat Res*. 2017;800-802:37-45.
12. Azarian B, Sajedin SM, Azimi A, Raigani M, Vaziri B, Davami F. Proteomics Profiling of Chimeric-Truncated Tissue Plasminogen activator Producing- Chinese Hamster Ovary Cells Cultivated in a Chemically Defined Medium Supplemented with Protein Hydrolysates. *Iran Biomed J*. 2017;21(3):154-66.
13. Ajourloo F, Vaezi M, Saadat A, Safaee SR, Gharib B, Ghanei M, et al. A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma. *PLoS One*. 2017;12(9):e0183969.
14. Mirzaei R, Saei A, Torkashvand F, Azarian B, Jalili A, Noorbakhsh F, et al. Identification of proteins derived from *Listeria monocytogenes* inducing human dendritic cell maturation. *Tumour Biol*. 2016;37(8):10893-907.
15. Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, et al. A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor. *Clin Appl Thromb Hemost*. 2016;22(2):184-90.
16. Azimzadeh Jamalkandi S, Mozhgani SH, Gholami Pourbadie H, Mirzaie M, Noorbakhsh F, Vaziri B, et al. Systems Biomedicine of Rabies Delineates the Affected Signaling Pathways. *Front Microbiol*. 2016;7:1688.
17. Torkashvand F, Vaziri B, Maleknia S, Heydari A, Vossoughi M, Davami F, et al. Designed Amino Acid Feed in Improvement of Production and Quality Targets of a Therapeutic Monoclonal Antibody. *PLoS One*. 2015;10(10):e0140597.
18. Jahandar H, Vaziri B, Nematollahi L, Afsharirad T, Mirabzadeh E, Torkashvand F, et al. Effect of Cysteamine on Cell Growth and IgG4 Production in Recombinant Sp2.0 Cells. *Iran J Pharm Res*. 2015;14(1):177-87.

19. Boghozian R, Saei A, Mirzaei R, Jamali A, Vaziri B, Razavi A, et al. Identification of *Toxoplasma gondii* protein fractions induce immune response against melanoma in mice. *APMIS*. 2015;123(9):800-9.
20. Zarei N, Vaziri B, Shokrgozar MA, Mahdian R, Fazel R, Khalaj V. High efficient expression of a functional humanized single-chain variable fragment (scFv) antibody against CD22 in *Pichia pastoris*. *Appl Microbiol Biotechnol*. 2014;98(24):10023-39.
21. Saei A, Boghozian R, Mirzaei R, Jamali A, Vaziri B, Hadjati J. *Listeria monocytogenes* protein fraction induces dendritic cells maturation and T helper 1 immune responses. *Iran J Allergy Asthma Immunol*. 2014;13(1):1-10.
22. Zandi F, Eslami N, Torkashvand F, Fayaz A, Khalaj V, Vaziri B. Expression changes of cytoskeletal associated proteins in proteomic profiling of neuroblastoma cells infected with different strains of rabies virus. *J Med Virol*. 2013;85(2):336-47.
23. Shahkarami MA, Vaziri B, Salami S, Harandi AA, Oger J. Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories. *J Immunol Methods*. 2013;388(1-2):46-8.
24. Rahimpour A, Vaziri B, Moazzami R, Nematollahi L, Barkhordari F, Kokabee L, et al. Engineering the cellular protein secretory pathway for enhancement of recombinant tissue plasminogen activator expression in Chinese hamster ovary cells: effects of CERT and XBP1s genes. *J Microbiol Biotechnol*. 2013;23(8):1116-22.
25. Mahboudi F, Abolhassan MR, Azarpanah A, Aghajani-Lazarjani H, Sadeghi-Haskoo MA, Maleknia S, et al. The Role of Different Supplements in Expression Level of Monoclonal Antibody against Human CD20. *Avicenna J Med Biotechnol*. 2013;5(3):140-7.
26. Farahtaj F, Zandi F, Khalaj V, Biglari P, Fayaz A, Vaziri B. Proteomics analysis of human brain tissue infected by street rabies virus. *Mol Biol Rep*. 2013;40(11):6443-50.
27. Vaziri B, Torkashvand F, Eslami N, Fayaz A. Comparative proteomics analysis of mice lymphocytes in early stages of infection by different strains of rabies virus. *Indian J Virol*. 2012;23(3):311-6.
28. Hajjarian H, Azarian B, Mohebbali M, Hadighi R, Assareh A, Vaziri B. Comparative proteomics study on meglumine antimoniate sensitive and resistant *Leishmania tropica* isolated from Iranian anthroponotic cutaneous leishmaniasis patients. *East Mediterr Health J*. 2012;18(2):165-71.
29. Rezaie F, Salimi M, Ghahremani MH, Vaziri B. Potential molecular targets in chemopreventative action of celecoxib: a proteomics analysis of J774.A1 macrophage-like cell line. *Mol Biosyst*. 2011;7(4):1306-11.
30. Rahmani M, Vaziri Bozorg SM, Ghasemi Esfe AR, Morteza A, Khalilzadeh O, Pedarzadeh E, et al. Evaluating the reliability of anatomic landmarks in safe lumbar puncture using magnetic resonance imaging: does sex matter? *Int J Biomed Imaging*. 2011;2011:868632.
31. Rahmani M, Ghasemi Esfe AR, Vaziri-Bozorg SM, Mazloumi M, Khalilzadeh O, Kahnouji H. The ultrasonographic correlates of carpal tunnel syndrome in patients with normal electrodiagnostic tests. *Radiol Med*. 2011;116(3):489-96.
32. Miroliaee AE, Esmaily H, Vaziri-Bami A, Baeri M, Shahverdi AR, Abdollahi M. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. *Toxicol Mech Methods*. 2011;21(3):200-8.
33. Khalaj V, Azarian B, Enayati S, Vaziri B. Annexin C4 in *A. fumigatus*: a proteomics approach to understand the function. *J Proteomics*. 2011;74(10):1950-8.
34. Doroud D, Zahedifard F, Vatanara A, Taslimi Y, Vahabpour R, Torkashvand F, et al. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid

nanoparticles against *Leishmania major* in BALB/c mice. *PLoS Negl Trop Dis*. 2011;5(7):e1236.

35. Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Taslimi Y, Vahabpour R, et al. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against *Leishmania major* infection. *J Control Release*. 2011;153(2):154-62.

36. Bolhassani A, Taheri T, Taslimi Y, Zamanilui S, Zahedifard F, Seyed N, et al. Fluorescent *Leishmania* species: development of stable GFP expression and its application for in vitro and in vivo studies. *Exp Parasitol*. 2011;127(3):637-45.

37. Ramazani A, Sardari S, Zakeri S, Vaziri B. In vitro antiplasmodial and phytochemical study of five *Artemisia* species from Iran and in vivo activity of two species. *Parasitol Res*. 2010;107(3):593-9.